Critical Care Therapeutics in Major Developed Markets
As per the new research findings the new and late-stage four-factor PCCs and recombinant products to drive critical care therapeutics market.
The critical care market across eight major countries (the US, UK, France, Germany, Italy, Spain, Japan and Canada) was worth an estimated $1.8 billion in 2013 and will grow to $2.5 billion by 2020, representing a Compound Annual Growth Rate (CAGR) of 4.7%.
The majority of revenue will continue to be generated by albumin sales, which will rise from $1.1 billion in 2013 to $1.6 billion by 2020.
Albumin was used to treat the highest share of the critical care patient population across all eight markets in 2013, with 2.2 million patients out of a total 2.4 million. GBI Research forecasts that albumin demand will increase at a CAGR of 15–20% over the next few years, and the approval of additional indications, such as treatment for Alzheimer’s disease, could contribute towards this growth.
"Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market" analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in critical care in the eight major developed markets: the US, UK, France, Germany, Italy, Spain, Japan and Canada.